Pharmaceutical intermediates
Entrectinib Intermediates
6 pharmaceutical intermediates for Entrectinib. Indication: Solid tumours; Carcinoma, Non-Small-Cell Lung.
About Entrectinib
- Originator
- Nerviano Medical Sciences Srl
- Indication
- Solid tumours; Carcinoma, Non-Small-Cell Lung
- Approved Date
- 08/15/2019
- DS/DP
- 07/08/2028
Available intermediates
6 intermediates currently listed for Entrectinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 5-(3,5-difluorobenzyl)-1H-indazol-3-amine | 1108745-30-7 | / | / |
| tert-butyl 4-(4-methylpiperazin-1-yl)-2-nitrobenzoate | 942271-61-6 | / | / |
| 5-(3,5-difluorobenzyl)-2-fluorobenzonitrile | 1108745-25-0 | / | / |
| tert-butyl 2-amino-4-(4-methylpiperazin-1-yl)benzoate | 1034975-35-3 | / | / |
| 4-(4-methylpiperazin-1-yl)-2-[(tetrahydropyran-4-yl)(2,2,2-trifluoroacetyl)amino]benzoic acid trifluoroacetate | 1034975-62-6 | / | / |
| 4-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzoicacid | 1034975-61-5 | / | / |
Building toward Entrectinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →